FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

Boehringer Ingelheim and Cue Biopharma have entered a strategic research partnership and licence agreement to develop and commercialise the latter’s CUE-501 product candidate for autoimmune conditions ...

Boehringer Ingelheim and Cue Biopharma Inc. have joined forces to develop and commercialize Cue Biopharma’s CUE-501 product candidate.

The Rheumatoid Arthritis Drugs/Therapeutics market revenue was $$ Million USD in 2022, grew to $$ Million USD in 2024, and will reach $$ Million USD in 2032, with a CAGR of $% during 2024-2032.

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies ...

We look forward to his continued partnership in his new role as a strategic advisor.” Dr. Banerjee added, "Artiva is leading ...

Pfizer and Flagship Pioneering have entered into an agreement aimed at discovering potential selective inhibitors for ...

Information and guidelines for 2022 for an authorized member of a partnership about how to complete and file a Partnership Information Return, and other related forms.

One of the most promising aspects of AI and its integration into the pharmaceutical industry is the technology’s potential to ...